Free Trial
→ Gold Alert: The Truth About Fort Knox Is Coming (From Golden Portfolio) (Ad) Buy SNDX Stock  Free SNDX Stock Alerts

Syndax Pharmaceuticals (SNDX) Financials

Syndax Pharmaceuticals logo
$13.33 +0.03 (+0.23%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$13.34 +0.01 (+0.08%)
As of 04/25/2025 04:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Syndax Pharmaceuticals

Annual Income Statements for Syndax Pharmaceuticals

This table shows Syndax Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders		 -26 -104 -47 -61 -74 -56 -77 25 -149 -209 -319
Consolidated Net Income / (Loss)		 -20 -24 -44 -61 -74 -56 -73 25 -149 -209 -319
Net Income / (Loss) Continuing Operations		 -20 -24 -44 -61 -74 -56 -73 25 -149 -209 -319
Total Pre-Tax Income 		-20 -24 -44 -61 -74 -56 -73 25 -149 -209 -319
Total Operating Income		 -21 -21 -44 -62 -76 -58 -71 26 -152 -230 -340
Total Gross Profit		 0.00 0.63 1.22 2.11 1.52 1.52 1.52 140 0.00 0.00 24
Total Revenue		 0.00 0.63 1.22 2.11 1.52 1.52 1.52 140 0.00 0.00 24
Operating Revenue		 0.00 0.63 1.22 2.11 1.52 1.52 1.52 140 0.00 0.00 24
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 21 21 45 64 77 59 73 113 152 230 363
Selling, General & Admin Expense		 11 12 13 16 17 16 23 25 33 67 121
Research & Development Expense		 10 9.55 32 48 60 43 50 88 118 163 242
Total Other Income / (Expense), net		 1.50 -3.61 -0.71 1.15 1.92 1.49 -1.74 -1.29 2.42 21 21
Interest Expense		 - - - - 0.00 0.00 2.36 1.90 3.14 0.21 4.93
Interest & Investment Income		 -0.29 -1.41 0.96 1.42 1.94 1.57 0.84 0.40 5.87 21 26
Other Gains / (Losses), net		 - - - - - - - - - - -0.25
Basic Earnings per Share		 ($453.02) ($1,519.27) ($3.22) ($2.90) ($2.92) ($1.84) ($1.87) $0.48 ($2.46) ($2.98) ($3.72)
Weighted Average Basic Shares Outstanding		 58.18K 68.35K 14.62M 21.00M 25.37M 30.49M 41.31M 52.06M 60.76M 70.37M 85.62M
Diluted Earnings per Share		 ($453.02) ($1,519.27) ($3.22) ($2.90) ($2.92) ($1.84) ($1.87) $0.46 ($2.46) ($2.98) ($3.72)
Weighted Average Diluted Shares Outstanding		 58.18K 68.35K 14.62M 21.00M 25.37M 30.49M 41.31M 53.62M 60.76M 70.37M 85.62M
Weighted Average Basic & Diluted Shares Outstanding		 58.18K 68.35K 14.62M 21.00M 25.37M 30.49M 41.31M 55.01M 68.44K 84.97M 86.02M

Quarterly Income Statements for Syndax Pharmaceuticals

This table shows Syndax Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Income / (Loss) Attributable to Common Shareholders		 -35 -39 -41 -45 -51 -72 -72 -68 -84 -94
Consolidated Net Income / (Loss)		 -35 -39 -41 -45 -51 -72 -72 -68 -84 -94
Net Income / (Loss) Continuing Operations		 -35 -39 -41 -45 -51 -72 -72 -68 -84 -94
Total Pre-Tax Income 		-35 -39 -41 -45 -51 -72 -72 -68 -84 -94
Total Operating Income		 -35 -42 -46 -50 -56 -78 -80 -74 -90 -96
Total Gross Profit		 0.00 - 0.00 0.00 0.00 - 0.00 3.50 13 7.68
Total Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 3.50 13 7.68
Operating Revenue		 0.00 - 0.00 - 0.00 - 0.00 3.50 13 7.68
Total Operating Expenses		 35 42 46 50 56 78 80 78 102 103
Selling, General & Admin Expense		 8.24 10 12 15 17 23 23 29 31 38
Research & Development Expense		 27 32 34 35 39 55 56 49 71 66
Total Other Income / (Expense), net		 -0.26 2.96 4.89 5.06 5.21 5.43 7.11 6.15 5.45 2.44
Interest Expense		 1.75 0.04 0.04 0.04 0.07 0.06 0.06 0.05 0.02 4.81
Interest & Investment Income		 1.78 2.99 5.08 5.19 5.35 5.55 7.26 6.28 5.44 7.11
Basic Earnings per Share		 ($0.58) ($0.63) ($0.59) ($0.64) ($0.73) ($1.02) ($0.85) ($0.80) ($0.98) ($1.09)
Weighted Average Basic Shares Outstanding		 60.67M 60.76M 69.44M 69.64M 69.86M 70.37M 85.21M 85.27M 85.43M 85.62M
Diluted Earnings per Share		 ($0.58) ($0.63) ($0.59) ($0.64) ($0.73) ($1.02) ($0.85) ($0.80) ($0.98) ($1.09)
Weighted Average Diluted Shares Outstanding		 60.67M 60.76M 69.44M 69.64M 69.86M 70.37M 85.21M 85.27M 85.43M 85.62M
Weighted Average Basic & Diluted Shares Outstanding		 60.22M 68.44K 68.82M 69.48M 69.64M 84.97M 84.99M 85.10M - 86.02M

Annual Cash Flow Statements for Syndax Pharmaceuticals

This table details how cash moves in and out of Syndax Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents		 -0.10 13 0.76 11 -1.40 -9.26 91 107 -148 221 -141
Net Cash From Operating Activities		 -14 -2.43 -35 -47 -69 -51 -71 29 -134 -161 -275
Net Cash From Continuing Operating Activities		 -14 -2.43 -35 -47 -69 -51 -72 29 -135 -161 -275
Net Income / (Loss) Continuing Operations		 -20 -24 -44 -61 -74 -56 -73 25 -149 -209 -319
Consolidated Net Income / (Loss)		 -20 -24 -44 -61 -74 -56 -73 25 -149 -209 -319
Depreciation Expense		 0.02 0.02 0.09 0.08 0.08 0.09 - - - - 0.01
Amortization Expense		 0.09 1.07 -0.13 -0.22 -0.56 -0.78 - 0.64 -3.38 -15 -13
Non-Cash Adjustments To Reconcile Net Income		 4.78 6.05 6.44 5.44 6.21 6.36 9.06 13 13 42 56
Changes in Operating Assets and Liabilities, net		 0.55 15 2.92 8.33 -0.30 -0.24 -7.93 -9.60 5.00 21 1.27
Net Cash From Investing Activities		 1.89 -62 -18 -17 51 13 -143 -41 -186 118 -220
Net Cash From Continuing Investing Activities		 1.89 -62 -18 -17 51 13 -143 -41 -186 118 -220
Purchase of Investments		 -3.39 -102 -158 -152 -79 -104 -279 -295 -495 -355 -557
Sale of Property, Plant & Equipment		 - - - - - - - 0.00 0.23 0.00 0.00
Sale and/or Maturity of Investments		 5.29 41 140 135 130 117 136 254 309 472 337
Net Cash From Financing Activities		 12 77 54 76 16 29 304 118 172 264 353
Net Cash From Continuing Financing Activities		 12 77 54 76 16 29 304 118 172 264 353
Issuance of Common Equity		 0.00 - 52 0.10 16 28 278 112 182 259 1.72
Other Financing Activities, net		 0.01 0.19 2.06 76 0.03 0.18 6.63 6.34 -9.54 5.13 352
Cash Interest Paid		 - - - - - - - - 2.06 0.00 0.00

Quarterly Cash Flow Statements for Syndax Pharmaceuticals

This table details how cash moves in and out of Syndax Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Net Change in Cash & Equivalents		 -49 2.98 -17 40 -2.73 201 -181 -9.22 28 21
Net Cash From Operating Activities		 -29 -23 -39 -35 -45 -41 -84 -72 -62 -57
Net Cash From Continuing Operating Activities		 -29 -24 -39 -35 -45 -42 -84 -71 -61 -59
Net Income / (Loss) Continuing Operations		 -35 -39 -41 -45 -51 -72 -72 -68 -84 -94
Consolidated Net Income / (Loss)		 -35 -39 -41 -45 -51 -72 -72 -68 -84 -94
Amortization Expense		 -1.04 -2.03 -3.97 -3.72 -3.66 -3.46 -3.82 -3.65 -3.06 -2.91
Non-Cash Adjustments To Reconcile Net Income		 14 4.32 8.43 10 4.59 19 9.14 6.01 16 25
Changes in Operating Assets and Liabilities, net		 -5.93 13 -2.57 2.86 5.49 15 -17 -5.63 10 13
Net Cash From Investing Activities		 -6.79 -138 20 74 40 -16 -99 62 87 -269
Net Cash From Continuing Investing Activities		 -6.79 -138 20 74 40 -16 -99 62 87 -269
Purchase of Investments		 -80 -251 -62 -81 -83 -129 -167 - -13 -376
Sale and/or Maturity of Investments		 73 113 82 155 123 113 68 62 100 107
Net Cash From Financing Activities		 -14 164 2.47 1.32 1.85 258 2.17 0.68 3.10 347
Net Cash From Continuing Financing Activities		 -14 164 2.47 1.32 1.85 258 2.17 0.68 3.10 347
Issuance of Common Equity		 0.11 162 0.20 0.18 0.26 258 0.31 0.24 0.54 0.63
Other Financing Activities, net		 -14 1.40 2.28 1.15 1.59 0.11 1.86 0.44 2.56 347

Annual Balance Sheets for Syndax Pharmaceuticals

This table presents Syndax Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Assets		 90 109 137 84 64 301 450 497 613 725
Total Current Assets		 88 109 133 83 62 299 448 490 581 603
Cash & Equivalents		 23 24 35 34 25 115 222 74 295 154
Short-Term Investments		 63 81 95 47 35 178 218 401 275 419
Accounts Receivable		 - - - - - - - - 0.00 11
Inventories, net		 - - - - - - - - 0.00 0.37
Prepaid Expenses		 1.46 3.03 3.36 2.33 2.56 5.68 1.45 1.92 3.29 8.54
Other Current Assets		 - - - - - - 6.89 12 6.89 10
Plant, Property, & Equipment, net		 0.09 0.26 0.27 0.37 0.28 0.19 0.28 0.02 0.01 0.00
Total Noncurrent Assets		 1.81 0.24 3.48 0.22 0.91 1.56 0.98 7.43 32 122
Long-Term Investments		 - - 3.25 - - - 0.00 5.47 30 120
Other Noncurrent Operating Assets		 1.81 0.24 0.23 0.22 0.91 1.56 0.98 1.96 2.17 2.24
Total Liabilities & Shareholders' Equity		 90 109 137 84 64 301 450 497 613 725
Total Liabilities		 23 25 33 31 32 48 41 30 59 437
Total Current Liabilities		 4.85 10 16 16 18 19 21 29 58 104
Short-Term Debt		 - - - - 0.00 2.29 - - 0.00 12
Accounts Payable		 1.45 2.38 2.23 1.44 6.18 3.51 5.67 4.35 9.96 12
Accrued Expenses		 2.18 6.77 12 13 10 11 14 24 40 60
Other Current Liabilities		 - - - - 0.48 0.32 0.55 0.44 8.28 20
Total Noncurrent Liabilities		 18 15 17 15 14 30 21 0.72 0.59 333
Long-Term Debt		 - - - - 0.00 18 20 0.00 0.00 332
Capital Lease Obligations		 - - - - - - 0.00 0.01 0.01 0.00
Other Noncurrent Operating Liabilities		 2.92 0.29 0.31 0.14 0.42 0.10 0.71 0.71 0.58 1.58
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -252 84 104 53 32 252 408 467 554 288
Total Preferred & Common Equity		 -252 84 104 53 32 252 408 467 554 288
Preferred Stock		 7.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -260 84 104 53 32 252 408 467 554 288
Common Stock		 0.00 389 471 492 527 821 952 1,161 1,456 1,509
Retained Earnings		 -260 -305 -366 -439 -495 -569 -544 -693 -902 -1,221
Accumulated Other Comprehensive Income / (Loss)		 0.03 0.06 -0.14 -0.03 0.00 -0.00 0.05 -0.81 0.22 0.16

Quarterly Balance Sheets for Syndax Pharmaceuticals

This table presents Syndax Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Total Assets		 360 460 431 399 543 477 426
Total Current Assets		 358 442 409 381 454 446 415
Cash & Equivalents		 71 58 97 95 115 105 133
Short-Term Investments		 266 375 302 269 320 320 257
Prepaid Expenses		 2.27 1.91 3.06 3.75 4.67 4.21 4.91
Other Current Assets		 17 5.81 7.22 14 15 17 20
Plant, Property, & Equipment, net		 0.02 0.02 0.01 0.01 0.01 0.00 0.00
Total Noncurrent Assets		 2.03 18 22 18 89 31 11
Long-Term Investments		 - 17 19 16 87 30 10
Other Noncurrent Operating Assets		 2.03 1.74 2.76 2.54 1.71 1.37 0.97
Total Liabilities & Shareholders' Equity		 360 460 431 399 543 477 426
Total Liabilities		 22 24 31 40 51 43 59
Total Current Liabilities		 21 24 30 39 51 42 59
Accounts Payable		 7.12 8.06 11 6.05 8.81 12 4.90
Accrued Expenses		 13 15 18 32 33 27 48
Other Current Liabilities		 0.48 0.45 1.46 1.01 8.60 4.10 6.36
Total Noncurrent Liabilities		 0.78 0.60 1.13 0.86 0.33 0.14 0.00
Capital Lease Obligations		 0.01 - 0.02 0.01 0.01 0.00 0.00
Other Noncurrent Operating Liabilities		 0.77 0.59 1.12 0.85 0.33 0.13 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 338 436 400 359 492 434 366
Total Preferred & Common Equity		 338 436 400 359 492 434 366
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 338 436 400 359 492 434 366
Common Stock		 994 1,170 1,179 1,190 1,467 1,478 1,493
Retained Earnings		 -654 -734 -779 -830 -975 -1,043 -1,127
Accumulated Other Comprehensive Income / (Loss)		 -1.61 - -0.57 -0.46 -0.76 -0.82 0.37

Annual Metrics and Ratios for Syndax Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Syndax Pharmaceuticals' official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 94.58% 72.79% -28.04% 0.00% 0.00% 9,109.56% -100.00% 0.00% 0.00%
EBITDA Growth		 0.00% -11.22% -110.30% -37.18% -22.47% 23.67% -22.87% 137.78% -674.36% -57.68% -44.05%
EBIT Growth		 0.00% -16.20% -100.08% -36.97% -21.99% 24.09% -24.34% 136.88% -675.55% -51.45% -47.48%
NOPAT Growth		 0.00% 3.84% -113.36% -41.56% -22.47% 24.17% -24.13% 152.44% -505.15% -51.53% -47.71%
Net Income Growth		 0.00% -21.64% -84.39% -36.72% -21.64% 24.22% -30.53% 134.07% -699.13% -40.19% -52.25%
EPS Growth		 0.00% -235.36% 99.79% 9.94% -0.69% 36.99% -1.63% 124.60% -634.78% -21.14% -24.83%
Operating Cash Flow Growth		 0.00% 83.13% -1,347.98% -34.74% -44.67% 26.15% -40.80% 140.88% -558.88% -20.14% -71.17%
Free Cash Flow Firm Growth		 0.00% 0.00% -631.17% -22.53% -51.68% 26.01% -43.00% 129.91% -708.16% -23.27% -73.98%
Invested Capital Growth		 0.00% 0.00% -7.54% -35.92% 3.59% -0.75% 25.92% 43.53% -17.14% -235.44% -30.82%
Revenue Q/Q Growth		 0.00% 0.00% 1.41% 72.79% -34.89% 0.00% 0.00% 933.89% -100.00% 0.00% 48.00%
EBITDA Q/Q Growth		 0.00% 0.00% -20.43% -17.08% 0.22% 8.22% -7.26% 130.23% -1,012.46% -18.16% -5.28%
EBIT Q/Q Growth		 0.00% 0.00% -21.78% -16.07% 0.27% 8.18% -7.64% 129.51% -988.26% -18.67% -5.68%
NOPAT Q/Q Growth		 0.00% 0.00% -17.32% -15.57% 0.21% 8.18% -8.60% 141.90% -660.20% -18.48% -5.75%
Net Income Q/Q Growth		 0.00% 0.00% -14.27% -15.78% 0.36% 7.94% -9.62% 127.18% -970.83% -18.90% -7.30%
EPS Q/Q Growth		 0.00% 0.00% 96.25% -152.17% 3.31% 13.21% 0.00% 125.41% -24,700.00% -15.06% -1.92%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% -21.08% -5.12% -3.51% 4.38% -4.25% 133.40% -1,227.19% -12.98% -6.20%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -0.77% -4.59% 2.27% -2.24% 124.30% -325.62% -11.09% -5.57%
Invested Capital Q/Q Growth		 0.00% 0.00% 2.49% -20.96% -9.99% 0.43% -14.12% -13.93% -8,571.78% -130.89% -82.52%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00%
EBITDA Margin		 0.00% -3,448.01% -3,726.64% -2,958.73% -5,035.14% -3,843.51% -4,722.61% 19.37% 0.00% 0.00% -1,491.14%
Operating Margin		 0.00% -3,271.61% -3,587.38% -2,938.99% -5,001.71% -3,792.95% -4,708.17% 18.77% 0.00% 0.00% -1,434.43%
EBIT Margin		 0.00% -3,621.21% -3,723.61% -2,951.76% -5,003.49% -3,798.15% -4,722.61% 18.91% 0.00% 0.00% -1,434.43%
Profit (Net Income) Margin		 0.00% -3,846.73% -3,645.25% -2,884.35% -4,875.48% -3,694.59% -4,822.54% 17.84% 0.00% 0.00% -1,346.11%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.08%
Interest Burden Percent		 101.48% 106.23% 97.90% 97.72% 97.44% 97.27% 102.12% 94.34% 98.20% 90.90% 93.77%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -36.16% -58.97% -64.53% -94.00% -132.43% -51.56% 7.55% -34.10% -40.98% -75.69%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -25.26% -45.68% -50.55% -68.65% -78.15% -39.35% 7.04% 0.00% 0.00% -50.78%
Return on Assets (ROA)		 0.00% -26.83% -44.71% -49.39% -66.90% -76.02% -40.18% 6.64% 0.00% 0.00% -47.66%
Return on Common Equity (ROCE)		 0.00% 140.77% 68.61% -64.53% -94.00% -132.43% -51.56% 7.55% -34.10% -40.98% -75.69%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 9.56% -52.86% -58.28% -139.43% -177.36% -29.01% 6.10% -31.95% -37.78% -110.63%
Net Operating Profit after Tax (NOPAT)		 -15 -14 -31 -43 -53 -40 -50 26 -106 -161 -238
NOPAT Margin		 0.00% -2,290.13% -2,511.16% -2,057.30% -3,501.20% -2,655.06% -3,295.72% 18.77% 0.00% 0.00% -1,004.10%
Net Nonoperating Expense Percent (NNEP)		 0.00% -22.56% -14.41% -14.60% -19.45% -22.40% -13.92% -0.37% -9.56% -8.95% -17.06%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - -22.72% -29.04% -37.63%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 1,848.64% 1,091.89% 752.42% 1,139.55% 1,058.80% 1,483.52% 18.07% 0.00% 0.00% 510.47%
R&D to Revenue		 0.00% 1,522.97% 2,595.49% 2,286.58% 3,962.16% 2,834.15% 3,324.65% 63.17% 0.00% 0.00% 1,020.47%
Operating Expenses to Revenue		 0.00% 3,371.61% 3,687.38% 3,038.99% 5,101.71% 3,892.95% 4,808.17% 81.23% 0.00% 0.00% 1,530.94%
Earnings before Interest and Taxes (EBIT)		 -20 -23 -45 -62 -76 -58 -72 26 -152 -230 -340
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -19 -22 -45 -62 -76 -58 -72 27 -155 -245 -353
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 1.55 2.05 2.08 7.54 3.60 2.65 3.28 2.72 3.90
Price to Tangible Book Value (P/TBV)		 0.00 0.00 1.55 2.05 2.08 7.54 3.60 2.65 3.28 2.72 3.90
Price to Revenue (P/Rev)		 0.00 0.00 106.92 101.35 72.85 157.08 599.16 7.74 0.00 0.00 47.51
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 43.38 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.31% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 20.46 38.11 19.45 117.60 419.16 4.73 0.00 0.00 32.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 24.42 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.02 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 25.21 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 22.69 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 38.58 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.08 0.05 0.00 0.00 1.19
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.07 0.05 0.00 0.00 1.15
Financial Leverage		 0.00 -1.30 -1.27 -1.27 -1.36 -1.66 -1.17 -1.05 -1.03 -1.06 -1.13
Leverage Ratio		 0.00 1.35 1.32 1.31 1.41 1.74 1.28 1.14 1.08 1.09 1.59
Compound Leverage Factor		 0.00 1.43 1.29 1.28 1.37 1.69 1.31 1.07 1.06 0.99 1.49
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7.39% 4.65% 0.00% 0.00% 54.40%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.84% 0.00% 0.00% 0.00% 1.92%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.55% 4.65% 0.00% 0.00% 52.48%
Preferred Equity to Total Capital		 0.00% 10.84% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 478.44% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -389.29% 100.00% 100.00% 100.00% 100.00% 92.61% 95.35% 100.00% 100.00% 45.60%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.28 0.74 0.00 0.00 -0.97
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 3.81 -15.52 3.10 2.45 0.99
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 -0.25 0.74 0.00 0.00 -0.94
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.40 0.76 0.00 0.00 -1.45
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 5.46 -16.02 4.53 3.73 1.47
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 -0.36 0.76 0.00 0.00 -1.39
Altman Z-Score		 0.00 0.00 -1.06 -0.29 -7.19 -8.58 8.95 15.66 29.02 13.11 -1.50
Noncontrolling Interest Sharing Ratio		 0.00% 489.29% 216.36% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.00 18.16 10.47 8.45 5.18 3.39 15.84 21.68 16.85 10.00 5.82
Quick Ratio		 0.00 17.84 10.16 8.23 5.02 3.25 15.53 21.27 16.37 9.82 5.64
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 5.49 -29 -36 -54 -40 -57 17 -104 -128 -223
Operating Cash Flow to CapEx		 -359,825.00% -4,955.10% -13,470.11% -56,394.05% -36,647.59% 0.00% 0.00% 22,582.17% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -24.31 9.02 -33.22 -617.58 -45.34
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -30.23 15.34 -42.61 -772.12 -55.77
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -30.23 15.27 -42.54 -772.12 -55.77
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.02 0.01 0.02 0.01 0.37 0.00 0.00 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 7.13 7.01 8.00 4.74 4.64 6.41 594.51 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.00 -20 -21 -29 -28 -28 -21 -12 -14 -46 -61
Invested Capital Turnover		 0.00 -0.06 -0.06 -0.08 -0.05 -0.05 -0.06 -8.56 0.00 0.00 -0.44
Increase / (Decrease) in Invested Capital		 0.00 -20 -1.50 -7.67 1.04 -0.21 7.30 9.09 -2.02 -33 -14
Enterprise Value (EV)		 0.00 0.00 25 80 30 178 636 661 1,051 904 776
Market Capitalization		 0.00 0.00 130 214 111 238 909 1,081 1,533 1,505 1,125
Book Value per Share		 $0.00 ($3,798.66) $4.62 $4.28 $2.14 $1.16 $6.17 $8.27 $7.76 $7.96 $3.37
Tangible Book Value per Share		 $0.00 ($3,798.66) $4.62 $4.28 $2.14 $1.16 $6.17 $8.27 $7.76 $7.96 $3.37
Total Capital		 0.00 67 84 104 53 32 272 428 467 554 632
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 20 20 0.01 0.01 344
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 18 20 0.01 0.01 332
Net Debt		 0.00 -87 -105 -133 -81 -60 -273 -420 -481 -601 -349
Capital Expenditures (CapEx)		 0.00 0.05 0.26 0.08 0.19 0.00 0.00 0.13 -0.23 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 -3.38 -7.34 -12 -14 -16 -11 -12 -15 -48 -61
Debt-free Net Working Capital (DFNWC)		 0.00 83 98 118 67 44 282 428 461 523 512
Net Working Capital (NWC)		 0.00 83 98 118 67 44 280 428 461 523 500
Net Nonoperating Expense (NNE)		 4.90 9.76 14 17 21 16 23 1.29 43 48 81
Net Nonoperating Obligations (NNO)		 0.00 -87 -105 -133 -81 -60 -273 -420 -481 -601 -349
Total Depreciation and Amortization (D&A)		 0.10 1.09 -0.04 -0.15 -0.48 -0.69 0.00 0.64 -3.38 -15 -13
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -539.55% -601.39% -589.94% -907.78% -1,049.90% -718.72% -8.83% 0.00% 0.00% -258.70%
Debt-free Net Working Capital to Revenue		 0.00% 13,263.16% 8,044.59% 5,580.83% 4,432.50% 2,898.02% 18,607.58% 306.15% 0.00% 0.00% 2,160.57%
Net Working Capital to Revenue		 0.00% 13,263.16% 8,044.59% 5,580.83% 4,432.50% 2,898.02% 18,456.95% 306.15% 0.00% 0.00% 2,109.41%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($453.02) ($1,519.27) ($3.22) ($2.90) ($2.92) ($1.84) $0.00 $0.48 ($2.46) ($2.98) ($3.72)
Adjusted Weighted Average Basic Shares Outstanding		 58.18K 68.35K 18.24M 24.70M 25.00M 30.24M 0.00 52.06M 60.76M 70.37M 85.62M
Adjusted Diluted Earnings per Share		 ($453.02) ($1,519.27) ($3.22) ($2.90) ($2.92) ($1.84) $0.00 $0.46 ($2.46) ($2.98) ($3.72)
Adjusted Weighted Average Diluted Shares Outstanding		 58.18K 68.35K 18.24M 24.70M 25.00M 30.24M 0.00 53.62M 60.76M 70.37M 85.62M
Adjusted Basic & Diluted Earnings per Share		 ($453.02) ($1,519.27) ($3.22) ($2.90) ($2.92) ($1.84) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 58.18K 68.35K 14.62M 21.00M 25.37M 30.49M 0.00 55.01M 68.44K 84.97M 86.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -15 -14 -31 -43 -53 -40 -50 18 -106 -161 -238
Normalized NOPAT Margin		 0.00% -2,290.13% -2,511.16% -2,057.30% -3,501.20% -2,655.06% -3,295.72% 13.14% 0.00% 0.00% -1,004.10%
Pre Tax Income Margin		 0.00% -3,846.73% -3,645.25% -2,884.35% -4,875.48% -3,694.59% -4,822.54% 17.84% 0.00% 0.00% -1,345.06%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -30.40 13.91 -48.48 -1,107.28 -68.91
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -21.21 13.81 -33.86 -773.88 -48.24
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -30.40 13.85 -48.41 -1,107.28 -68.91
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 -21.21 13.74 -33.79 -773.88 -48.24
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Syndax Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Syndax Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -81.66% -145.58% -35.84% -40.71% -64.76% -84.80% -66.42% -45.74% -54.13% -21.93%
EBIT Growth		 -76.54% -143.49% -25.24% -31.83% -59.22% -85.47% -72.44% -49.29% -58.71% -23.61%
NOPAT Growth		 -75.42% -130.73% -24.84% -31.69% -60.37% -85.34% -72.80% -49.39% -58.95% -23.69%
Net Income Growth		 -71.53% -140.74% -10.65% -18.75% -44.47% -84.91% -76.04% -52.56% -64.48% -29.94%
EPS Growth		 -45.00% -134.24% 6.35% -3.23% -25.86% -61.90% -44.07% -25.00% -34.25% -6.86%
Operating Cash Flow Growth		 -14.43% -122.73% 6.45% 12.24% -56.44% -80.61% -112.98% -102.55% -39.57% -38.79%
Free Cash Flow Firm Growth		 -59.83% -131.62% 53.95% 71.95% 45.25% 19.64% -93.85% -271.76% -157.83% -141.47%
Invested Capital Growth		 101.58% -17.14% -329.83% -683.64% -12,407.98% -235.44% -103.02% -11.21% -65.50% -30.82%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 257.14% -38.56%
EBITDA Q/Q Growth		 4.07% -20.83% -13.77% -6.70% -12.33% -35.52% -2.46% 6.56% -18.80% -7.21%
EBIT Q/Q Growth		 6.14% -18.62% -9.82% -7.82% -13.36% -38.18% -2.10% 6.66% -20.51% -7.62%
NOPAT Q/Q Growth		 6.85% -19.62% -9.47% -7.96% -13.44% -38.24% -2.06% 6.66% -20.70% -7.58%
Net Income Q/Q Growth		 5.77% -10.71% -4.93% -8.48% -14.64% -41.70% 0.10% 5.99% -23.60% -11.94%
EPS Q/Q Growth		 6.45% -8.62% 6.35% -8.47% -14.06% -39.73% 16.67% 5.88% -22.50% -11.22%
Operating Cash Flow Q/Q Growth		 29.18% 19.79% -71.35% 9.83% -26.24% 7.40% -102.06% 14.25% 13.01% 7.92%
Free Cash Flow Firm Q/Q Growth		 26.64% 21.95% 23.97% 35.57% -43.20% -14.56% -83.39% -23.57% 0.69% -7.29%
Invested Capital Q/Q Growth		 -94.78% -8,571.78% -7.36% -22.95% -10.07% -130.89% 35.02% 32.65% -63.79% -82.52%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,227.17% -740.82% -1,292.64%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,120.46% -716.62% -1,254.75%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,122.91% -716.36% -1,254.75%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,944.66% -673.01% -1,226.16%
Tax Burden Percent		 100.00% 100.30% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.26%
Interest Burden Percent		 99.91% 92.97% 89.09% 89.64% 90.65% 92.96% 90.95% 91.60% 93.95% 97.46%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -5.19% -34.10% -37.85% -42.08% -50.50% -40.98% -51.89% -63.30% -81.88% -75.69%
Cash Return on Invested Capital (CROIC)		 -15,020.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -16.36% -27.78% -44.42%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -14.99% -26.10% -43.41%
Return on Common Equity (ROCE)		 -5.19% -34.10% -37.86% -42.08% -50.50% -40.98% -51.91% -63.30% -81.88% -75.69%
Return on Equity Simple (ROE_SIMPLE)		 -4.12% 0.00% -35.20% -40.08% -49.02% 0.00% -48.92% -60.80% -81.07% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -29 -32 -35 -39 -55 -56 -52 -63 -67
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,484.32% -501.63% -878.33%
Net Nonoperating Expense Percent (NNEP)		 -3.95% -2.17% -2.15% -2.53% -3.26% -3.32% -3.44% -3.69% -5.50% -5.63%
Return On Investment Capital (ROIC_SIMPLE)		 - -6.29% - - - -9.84% - - - -10.68%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 830.31% 248.85% 490.76%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1,390.14% 567.77% 853.24%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,220.46% 816.62% 1,344.00%
Earnings before Interest and Taxes (EBIT)		 -35 -42 -46 -50 -56 -78 -80 -74 -90 -96
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -44 -50 -53 -60 -81 -83 -78 -93 -99
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 4.02 3.28 0.00 3.60 2.81 2.72 3.37 4.02 4.47 3.90
Price to Tangible Book Value (P/TBV)		 4.02 3.28 0.00 3.60 2.81 2.72 3.37 4.02 4.47 3.90
Price to Revenue (P/Rev)		 10.74 0.00 0.00 0.00 0.00 0.00 0.00 498.51 102.38 47.51
Price to Earnings (P/E)		 98.75 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 6,265.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 8.07 0.00 0.00 0.00 0.00 0.00 0.00 368.62 77.40 32.78
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.19
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.15
Financial Leverage		 -1.02 -1.03 -1.02 -1.02 -1.03 -1.06 -1.05 -1.05 -1.07 -1.13
Leverage Ratio		 1.12 1.08 1.09 1.10 1.09 1.09 1.08 1.09 1.14 1.59
Compound Leverage Factor		 1.11 1.01 0.97 0.99 0.99 1.01 0.98 1.00 1.07 1.55
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 54.40%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.92%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 52.48%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.08% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 45.60%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.97
Net Debt to EBITDA		 24.18 3.10 0.00 2.28 1.83 2.45 1.87 1.50 1.19 0.99
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.94
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.45
Net Debt to NOPAT		 24.18 4.53 0.00 3.46 2.79 3.73 2.83 2.26 1.78 1.47
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.39
Altman Z-Score		 36.39 29.75 -1.44 25.76 12.77 13.93 17.34 22.02 13.19 -0.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% -0.04% 0.00% 0.00% 0.00% -0.04% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 17.19 16.85 18.61 13.56 9.73 10.00 8.93 10.50 6.99 5.82
Quick Ratio		 16.24 16.37 18.23 13.22 9.28 9.82 8.55 10.01 6.56 5.64
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -35 -27 -21 -13 -19 -22 -40 -50 -50 -53
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 -20.09 -637.27 -520.86 -383.56 -274.62 -349.56 -734.31 -1,109.05 -2,154.95 -11.06
Operating Cash Flow to Interest Expense		 -16.33 -532.42 -980.70 -1,010.60 -637.90 -656.33 -1,519.05 -1,592.11 -2,709.65 -11.94
Operating Cash Flow Less CapEx to Interest Expense		 -16.20 -532.42 -980.70 -1,010.60 -637.90 -656.33 -1,519.05 -1,592.11 -2,709.65 -11.94
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.42 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.04 0.04
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1,398.63 0.00 0.00 0.00 0.00 0.00 0.00 466.67 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 0.16 -14 -15 -18 -20 -46 -30 -20 -33 -61
Invested Capital Turnover		 -24.86 0.00 0.00 0.00 0.00 0.00 0.00 -0.18 -0.60 -0.44
Increase / (Decrease) in Invested Capital		 11 -2.02 -11 -21 -20 -33 -15 -2.04 -13 -14
Enterprise Value (EV)		 1,021 1,051 -448 1,022 630 904 1,135 1,290 1,238 776
Market Capitalization		 1,359 1,533 1.45 1,440 1,009 1,505 1,657 1,745 1,638 1,125
Book Value per Share		 $5.98 $7.76 $6,368.03 $5.81 $5.17 $7.96 $5.77 $5.11 $4.31 $3.37
Tangible Book Value per Share		 $5.98 $7.76 $6,368.03 $5.81 $5.17 $7.96 $5.77 $5.11 $4.31 $3.37
Total Capital		 338 467 436 400 359 554 492 434 366 632
Total Debt		 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.00 0.00 344
Total Long-Term Debt		 0.01 0.01 0.00 0.02 0.01 0.01 0.01 0.00 0.00 332
Net Debt		 -338 -481 -449 -418 -379 -601 -522 -455 -400 -349
Capital Expenditures (CapEx)		 -0.23 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -1.13 -15 -15 -20 -22 -48 -31 -22 -34 -61
Debt-free Net Working Capital (DFNWC)		 337 461 418 379 342 523 403 404 355 512
Net Working Capital (NWC)		 337 461 418 379 342 523 403 404 355 500
Net Nonoperating Expense (NNE)		 11 9.77 8.92 9.84 12 18 17 16 21 27
Net Nonoperating Obligations (NNO)		 -338 -481 -450 -418 -379 -601 -522 -455 -400 -349
Total Depreciation and Amortization (D&A)		 -1.03 -2.03 -3.96 -3.72 -3.66 -3.46 -3.82 -3.65 -3.06 -2.91
Debt-free, Cash-free Net Working Capital to Revenue		 -0.89% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -614.66% -213.59% -258.70%
Debt-free Net Working Capital to Revenue		 266.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11,530.97% 2,221.45% 2,160.57%
Net Working Capital to Revenue		 266.11% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 11,530.97% 2,221.45% 2,109.41%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.58) ($0.63) ($0.59) ($0.64) ($0.73) ($1.02) ($0.85) ($0.80) ($0.98) ($1.09)
Adjusted Weighted Average Basic Shares Outstanding		 60.67M 60.76M 69.44M 69.64M 69.86M 70.37M 85.21M 85.27M 85.43M 85.62M
Adjusted Diluted Earnings per Share		 ($0.58) ($0.63) ($0.59) ($0.64) ($0.73) ($1.02) ($0.85) ($0.80) ($0.98) ($1.09)
Adjusted Weighted Average Diluted Shares Outstanding		 60.67M 60.76M 69.44M 69.64M 69.86M 70.37M 85.21M 85.27M 85.43M 85.62M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 60.22M 68.44K 68.82M 69.48M 69.64M 84.97M 84.99M 85.10M 0.00 86.02M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -29 -32 -35 -39 -55 -56 -52 -63 -67
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,484.32% -501.63% -878.33%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1,944.66% -673.01% -1,222.94%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -20.27 -977.53 -1,154.05 -1,422.03 -806.01 -1,237.48 -1,447.29 -1,651.16 -3,893.26 -20.05
NOPAT to Interest Expense		 -14.07 -684.27 -805.26 -993.56 -563.55 -865.62 -1,012.00 -1,154.47 -2,726.26 -14.04
EBIT Less CapEx to Interest Expense		 -20.14 -977.53 -1,154.05 -1,422.03 -806.01 -1,237.48 -1,447.29 -1,651.16 -3,893.26 -20.05
NOPAT Less CapEx to Interest Expense		 -13.94 -684.27 -805.26 -993.56 -563.55 -865.62 -1,012.00 -1,154.47 -2,726.26 -14.04
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Syndax Pharmaceuticals' Financials

When does Syndax Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Syndax Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Syndax Pharmaceuticals' net income changed over the last 10 years?

Syndax Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$318.76 million in 2024, rising from -$19.83 million in 2014. The previous period was -$209.36 million in 2023.

What is Syndax Pharmaceuticals's operating income?
Syndax Pharmaceuticals's total operating income in 2024 was -$339.67 million, based on the following breakdown:
  • Total Gross Profit: $23.68 million
  • Total Operating Expenses: $362.53 million
How has Syndax Pharmaceuticals revenue changed over the last 10 years?

Over the last 10 years, Syndax Pharmaceuticals' total revenue changed from $0.00 in 2014 to $23.68 million in 2024, a change of 2,368,000,000.0%.

How much debt does Syndax Pharmaceuticals have?

Syndax Pharmaceuticals' total liabilities were at $436.69 million at the end of 2024, a 644.1% increase from 2023, and a 1,781.9% increase since 2015.

How much cash does Syndax Pharmaceuticals have?

In the past 9 years, Syndax Pharmaceuticals' cash and equivalents has ranged from $23.18 million in 2015 to $295.39 million in 2023, and is currently $154.08 million as of their latest financial filing in 2024.

How has Syndax Pharmaceuticals' book value per share changed over the last 10 years?

Over the last 10 years, Syndax Pharmaceuticals' book value per share changed from 0.00 in 2014 to 3.37 in 2024, a change of 336.5%.


Related Companies

This page (NASDAQ:SNDX) was last updated on 4/28/2025 by MarketBeat.com Staff
From Our Partners
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...
Stansberry Research | Sponsored
Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...
Golden Portfolio | Sponsored
Collect $7k per month from Tesla’s SECRET dividend
Tesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...
Investors Alley | Sponsored
Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...
Altimetry | Sponsored
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
The July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...
Crypto Swap Profits | Sponsored
The Last Time This Happened, Americans Lost Billions
Wall Street leaders just held a secret meeting in Las Vegas. What they discussed mirrors 2006 — and the warnin...
Banyan Hill Publishing | Sponsored
Altucher: Turn $900 into $108,000 in just 12 months?
We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.
Paradigm Press | Sponsored
Is he more powerful than Trump?
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored